GI Insights

Guest: Anthony J. Lembo, MD

IBS is a common disorder affecting 10% to 15% of the adult population. IBS-D can be diagnosed using symptom-based criteria, a detailed physical exam, and select tests to exclude organic diseases. In this activity, clinicians will learn screening and detection methods for IBS-D, including ROME IV criteria, alarm features, and select tests such as complete blood count, C-reactive protein /stool calprotectin, tissue transglutaminase (IgA and IgG), stool analysis, and assessment for bile acid malabsorption.

Guest: Jeffrey B. Danzig, MD

Patients with IBS-D may spend years before they are accurately diagnosed, with their symptoms often being labeled as psychosomatic. Considering the potential underlying cause of IBS-D can help guide diagnosis as well as the choice of appropriate treatment. In this activity, clinicians will learn screening methods and factors in the pathophysiology of IBS-D to more accurately diagnosis patients and select appropriate treatment, along with patient-clinician communication strategies that can improve outcomes.

Guest: Darren M. Brenner, MD, AGAF

Patients with IBS-D often try multiple medications that fail to treat their symptoms. IBS has a heterogeneous pathogenesis, and there are no specific algorithms for treatment subtypes. In this activity, clinicians will learn treatment options to consider for patients with IBS-D in whom some previous therapies have failed.

Guest: Bincy P. Abraham, MD, MS

Guest: Jason Ken Hou, MD, MS, FACG

Guest: Siddharth Singh, MD

As the most common extraintestinal complication from IBD, iron deficiency anemia (IDA) can take a heavy toll on your patients’ quality of life. This activity will review those impacts, in addition to discussing the different therapies and resources that are available to both you and your IBD patients.

Guest: Adam S. Cheifetz, MD

Guest: Alan C. Moss, MD

This innovative, case-based CME activity features two prominent faculty covering important, timely issues and data related to the treatment and monitoring of inflammatory bowel disease (IBD). Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. Topics will include:

• Challenges with TNF Inhibitor Treatment for IBD
• Why Reactive and Proactive Therapeutic Drug Monitoring Optimizes Treatment
• Case Studies on Algorithmic Therapeutic Drug Monitoring

Guest: Robert G. Gish, MD

In 2015, there were an estimated 291,150 new cases of digestive system cancers in the United States, with an estimated 149,300 deaths (American Cancer Society, 2015). Having access to the most recent clinical advances in GI malignancies is crucial to making informed and timely treatment decisions. In this activity, an expert faculty member will highlight the most exciting and compelling data in hepatocellular carcinoma (HCC), and provide insights on how these clinical advances may be practice changing.

Guest: David H. Ilson, MD, PhD

In 2015, there were an estimated 291,150 new cases of digestive system cancers in the United States, with an estimated 149,300 deaths (American Cancer Society, 2015). Having access to the most recent clinical advances in GI malignancies is crucial to making informed and timely treatment decisions. In this activity, an expert faculty member will highlight the most exciting and compelling data in gastric cancer, and provide insights on how these clinical advances may be practice changing.

Guest: Pamela L. Kunz, MD

In 2015, there were an estimated 291,150 new cases of digestive system cancers in the United States, with an estimated 149,300 deaths (American Cancer Society, 2015). Having access to the most recent clinical advances in GI malignancies is crucial to making informed and timely treatment decisions. In this activity, an expert faculty member will highlight the most exciting and compelling data in pancreatic cancer, pancreatic neuroendocrine tumors (pNET), and GI neuroendocrine tumors (GI-NET), and provide insights on how these clinical advances may be practice changing.

Guest: J. Randolph Hecht, MD

In 2015, there were an estimated 291,150 new cases of digestive system cancers in the United States, with an estimated 149,300 deaths (American Cancer Society, 2015). Having access to the most recent clinical advances in GI malignancies is crucial to making informed and timely treatment decisions. In this activity, an expert faculty member will highlight the most exciting and compelling data in colorectal cancer (CRC), and provide insights on how these clinical advances may be practice changing.

Host: Barnett Mennen, MD

Physician Quality Reporting Systems, or PQRS, are here to stay in clinical medicine. Within the field of gastroenterology, understanding the metrics of PQRS can make a substantial difference in the success of a practice. Joining host Dr. Barry Mennen to detail the ins and outs of PQRS in gastroenterology is Dr. Ziad Gellad, Assistant Professor of Medicine, Director of Quality in the Division of Gastroenterology, and Director of Clinical Improvement in the Department of Medicine at Duke University Medical Center.